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Abstract
Objective To assess the association between leucocyte telomere length
and risk of cardiovascular disease.
Design Systematic review and meta-analysis.
Data sources Studies published up to March 2014 identified through
searches of Medline, Web of Science, and Embase.
Eligibility criteria Prospective and retrospective studies that reported
on associations between leucocyte telomere length and coronary heart
disease (defined as non-fatal myocardial infarction, coronary heart
disease death, or coronary revascularisation) or cerebrovascular disease
(defined as non-fatal stroke or death from cerebrovascular disease) and
were broadly representative of general populations—that is, they did not
select cohort or control participants on the basis of pre-existing
cardiovascular disease or diabetes.
Results Twenty four studies involving 43 725 participants and 8400
patients with cardiovascular disease (5566 with coronary heart disease
and 2834 with cerebrovascular disease) were found to be eligible. In a
comparison of the shortest versus longest third of leucocyte telomere
length, the pooled relative risk for coronary heart disease was 1.54 (95%
confidence interval 1.30 to 1.83) in all studies, 1.40 (1.15 to 1.70) in
prospective studies, and 1.80 (1.32 to 2.44) in retrospective studies.
Heterogeneity between studies was moderate (I2=64%, 41% to 77%,
Phet<0.001) and was not significantly explained by mean age of
participants (P=0.23), the proportion of male participants (P=0.45), or
distinction between retrospective versus prospective studies (P=0.32).
Findings for coronary heart disease were similar in meta-analyses
restricted to studies that adjusted for conventional vascular risk factors
(relative risk 1.42, 95% confidence interval 1.17 to 1.73); studies with
≥200 cases (1.44, 1.20 to 1.74); studies with a high quality score (1.53,
1.22 to 1.92); and in analyses that corrected for publication bias (1.34,
1.12 to 1.60). The pooled relative risk for cerebrovascular disease was
1.42 (1.11 to 1.81), with no significant heterogeneity between studies
(I2=41%, 0% to 72%, Phet=0.08). Shorter telomeres were not significantly
associated with cerebrovascular disease risk in prospective studies
(1.14, 0.85 to 1.54) or in studies with a high quality score (1.21, 0.83 to
1.76).
Conclusion Available observational data show an inverse association
between leucocyte telomere length and risk of coronary heart disease
independent of conventional vascular risk factors. The association with
cerebrovascular disease is less certain.
Introduction
Chronological age is one of the strongest predictors of
cardiovascular disease but is not considered to be a causal factor.
Rather, this relation might reflect the impact of biological
ageing, particularly the accumulation of endothelial damage
over time, because of various mechanical, haemodynamic, and
immunological mechanisms.1 Telomeres are DNA-protein
structures at the end of linear chromosomes and have been
proposed as markers of the biological ageing process because
they shorten with each cell division, thereby reflecting the
amount of cellular turnover within an individual; their length
varies considerably between individuals, including those of the
same chronological age; and the rate of attrition of telomere
length has been linked to exposure to high oxidative stress and
inflammation, both of which are considered important drivers
of biological ageing.2 3 In addition, as telomere length within
individuals is generally strongly correlated across tissue types,
leucocyte based measures might also serve as a marker of
telomere length in less accessible tissues.4
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Because of its presumed role in biological ageing, telomere
length has been proposed as a general risk factor for age related
chronic diseases, such as cancer, type 2 diabetes, and
cardiovascular disease.5Although previous meta-analyses have
shown inverse associations between leucocyte telomere length
and cancer and diabetes,6-8 the association of telomeres with
cardiovascular disease has not yet been systematically assessed.
Interpretation of the available evidence for cardiovascular
disease has been hindered by studies that used different study
designs (such as prospective versus retrospective), application
of different assay methods, and/or reporting relative risks for
different disease outcomes (such as coronary heart disease or
stroke). In addition, many previous studies of telomere length
and cardiovascular disease have not reported easily comparable
measures of association, such as risk ratios or odds ratios,
making their interpretation difficult. Previous studies have also
typically been underpowered to assess the association with
cardiovascular disease in different population subgroups, such
as by age and sex.
We therefore conducted a systematic review and meta-analysis
of published studies to assess the association between leucocyte
telomere length and cardiovascular disease outcomes.We aimed
to precisely quantify any associations in a systematic way and
to evaluate and compare these associations across a wide range
of study level characteristics.
Methods
Literature search and study selection
The meta-analysis was conducted according to the MOOSE
guidelines.9 We searched for studies that published on
associations between leucocyte telomere length and coronary
heart disease or cerebrovascular disease in Medline, Web of
Science, and Embase up to 20 March 2014 (see fig 1 in
appendix). The search strategy combined terms related to
telomere length with those related to the outcomes of
cardiovascular disease, coronary heart disease, and
cerebrovascular disease (see table 1 in appendix) without
language restrictions.We complemented the search by scanning
reference lists of the identified articles. Studies were eligible
for inclusion if they reported on associations between baseline
leucocyte telomere length and coronary heart disease (defined
as non-fatal myocardial infarction, coronary heart disease death,
or coronary revascularisation) or cerebrovascular disease
(defined as non-fatal stroke or death from cerebrovascular
disease) and were broadly representative of general
populations—that is, they did not select participants (in cohort
studies) or controls (in case-control studies) on the basis of
pre-existing cardiovascular diseases or diabetes. Both
prospective and retrospective studies were eligible (where
retrospective indicates that telomere length was measured in
DNA samples collected after diagnosis of disease). Retrospective
studies included case-control and cross sectional studies;
prospective studies included nested case-control and prospective
cohort studies. Two investigators independently identified
eligible studies; discrepancies were resolved by consensus with
a third investigator.
Data extraction
For each article, we used a standardised abstraction form to
extract information on geographical location, year of publication,
mean and standard deviation of age of participants, proportion
of male participants, outcome definition, population source,
assay methods, number of experimental replicates, assay
coefficient of variation, tissue source of DNA, correlation
coefficients between telomere length and age, the mean and
standard deviation of telomere length in cases and controls,
reported estimates of the association with outcome, and degree
of statistical adjustment for covariates. Additional information
was obtained through correspondence with study authors.
Information on study quality was assessed with the
Newcastle-Ottawa scale, which varies from zero to a maximum
possible score of nine and incorporates information on
participant selection, outcome ascertainment, exposure
ascertainment, and the potential for confounding.10
Statistical analysis
The overall cross sectional correlation between telomere length
and age was estimated in cohort studies or controls in
case-control studies. Study specific correlation coefficients were
transformed to approximate normality based on Fisher’s z
transformation and combined across studies with random effects
meta-analysis.When the correlation coefficient was not reported,
we estimated it from the t statistic of the linear association
between telomere length and age, if available, or contacted
authors.
We calculated summary relative risks for the association
between telomere length and coronary heart disease or
cerebrovascular disease by random effects meta-analysis of
study specific estimates. Hazard ratios, risk ratios, and odds
ratios were assumed to approximate the samemeasure of relative
risk. The study specific relative risk estimates were transformed
to a common scale of comparison before meta-analysis
(corresponding to a comparison of risk in the shortest versus
longest third of the distribution of telomere length) by using
methods previously described.11 For example, under the
assumption of normality of the distribution of telomere length
and a log linear association with disease risk, the log relative
risk for the shortest versus longest third of the distribution of
telomere length is expected to be about 2.18 times the log
relative risk for a 1 SD decrease in telomere length. The standard
error of the transformed log relative risk was calculated by
applying the samemultiplication factor to the originally reported
standard error (or that inferred from the reported P value).When
they were not reported, we obtained relative risks through
correspondence with the study authors or estimated from the
mean difference in telomere length between cases and controls,
using a previously described method.11 For the WTCCC
study,12 13which did not report a relative risk estimate, we could
not derive an estimate based on the preceding approximation
because the reported variances of telomere length in cases and
controls were markedly different, and this study was therefore
excluded. When studies reported relative risks with different
degrees of statistical adjustment for confounding, we used the
most adjusted estimate. For the WOSCOPS trial,14 we used the
relative risk estimated from the placebo group. We assessed
evidence of publication bias or small study effects using funnel
plots and Egger’s test15 and by comparing pooled results from
studies involving ≥200 cases with those from smaller studies.
We used Duval’s non-parametric “trim and fill” method to
estimate the relative risk making allowance for publication
bias.16
We assessed heterogeneity between studies with Cochran’s Q
test and the I2 statistic.17 Sources of heterogeneity were assessed
by comparing results grouped according to study level
characteristics and by using meta-regression to assess the
significance of differences. Although these results are presented
categorically, the P values from meta-regression on continuous
study level characteristics (that is, mean age, age standard
deviation, proportion of males, Newcastle-Ottawa scale score,
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assay coefficient of variation, number of experimental replicates,
and number of cases) reflect the linear test of association. The
study level characteristics tested as sources of heterogeneity
were geographical location (Europe versusNorthAmerica versus
Asia), population source (population based versus not),
Newcastle-Ottawa scale score, mean age of participants, standard
deviation of age of participants (for the correlation between
telomere length and age only), proportion of male participants,
assay method (quantitative polymerase chain reaction (qPCR)
versus others), assay coefficient of variation, DNA extraction
method (QiaAMP versus salting out versus other/unspecified),
number of assay replicates, number of cases, case definition,
and degree of adjustment for covariates, including conventional
vascular risk factors (defined as age, sex, body mass index
(BMI), smoking, history of diabetes, blood pressure, and lipid
markers). All analyses were performed with Stata release 13.1
(StataCorp, College Station, TX). Statistical tests were two sided
with a significance threshold of P<0.05.
Results
The literature search strategy identified 1500 unique articles
across Medline, Web of Science, and Embase (see fig 1 in
appendix). After the initial screen of titles and abstracts, 76
articles remained for further investigation. We obtained
previously unpublished results on stroke from the Scottish
Mental Survey through correspondence. After detailed
assessments, 26 articles/unpublished reports, corresponding to
24 independent studies, were found to meet the inclusion criteria
and were included in the meta-analysis.14 18-41
The table (and table 2 in the appendix) summarises
characteristics of the included studies.⇓ In aggregate, the studies
involved 43 725 individuals, including 8400 cases of
cardiovascular disease (5566 with coronary heart disease and
2834 with cerebrovascular disease). Twelve studies had a
prospective design (30 510 participants), and 12 had a
retrospective design (13 215 participants). Twelve studies were
conducted in Europe, seven in North America, and five in Asia.
Twenty one studies measured telomere length using qPCR
(quantitative polymerase chain reaction), whereas two studies
used Southern blotting and one used flow-FISH (fluorescent in
situ hybridisation). The weighted mean age of participants was
60 (range 40-90), and 53% were men (range 0-100%). Within
the included studies, there was a weak inverse correlation
between telomere length and chronological age (r=−0.13, 95%
confidence interval −0.18 to −0.08), with substantial
heterogeneity between studies (I2=94%, 95% confidence interval
92% to 96%) (see fig 2 in appendix). The heterogeneity in
reported correlations was mostly attributable to the studies’
quality, size, and age variability, which collectively explained
80% of the heterogeneity between studies (residual I2=66%)
(see fig 3 in appendix). The correlation between telomere length
and age was −0.22 (95% confidence interval −0.27 to −0.16)
in studies with a higher quality score (Newcastle-Ottawa scale
score ≥8); −0.16 (−0.22 to −0.10) in studies with higher age
variability (SD of age ≥8 years); and −0.20 (−0.25 to −0.14)
in larger studies (n>1000).
As shown in figure 1⇓, the pooled relative risk for coronary
heart disease comparing shortest third v longest third of telomere
length was 1.54 (95% confidence interval 1.30 to 1.83; 20
studies), with moderate heterogeneity between studies (I2=64%,
95% confidence interval 41% to 77%; Phet<0.001). The pooled
relative risk for coronary heart disease was 1.40 (1.15 to 1.70)
in prospective studies and 1.80 (1.32 to 2.44) in retrospective
studies (P=0.32 for difference).
Figure 2⇓ shows the results by potential sources of heterogeneity
among studies of coronary heart disease, including various
clinically relevant subgroups andmethodological factors. Pooled
relative risk estimates for coronary heart disease did not differ
significantly by any of the study level characteristics tested,
including geographical location, population source, study
quality, mean age, proportion ofmale participants, assaymethod,
assay coefficient of variation, DNA extraction method, number
of experimental replicates, number of cases, case definition,
and degree of statistical adjustment (all P≥0.15). The pooled
relative risk for coronary heart disease in the shortest versus
longest third of telomere length was 1.59 (95% confidence
interval 1.15 to 2.22) in three studies that adjusted for
conventional vascular risk factors, 1.34 (1.04 to 1.74) in four
studies that adjusted for conventional vascular risk factors plus
C reactive protein and physical activity, and 1.42 (1.17 to 1.73)
in these seven studies combined. The corresponding association
was 1.53 (1.22 to 1.92) in the seven highest quality studies and
1.44 (1.20 to 1.74) in eight studies with ≥200 cases.
A funnel plot of the relative risk estimates for coronary heart
disease was consistent with the presence of publication bias,
which was supported by a significant Egger’s regression
asymmetry test (P<0.001) (see fig 4 in appendix). Using the
“trim and fill” method, we estimated that in the absence of
publication bias, the combined relative risk for coronary heart
disease with shorter telomere length would have been 1.34 (95%
confidence interval 1.12 to 1.60), weaker than the uncorrected
association (1.54, 1.30 to 1.83) but still significant (P=0.001).
The pooled relative risk for cerebrovascular disease, for shortest
third v longest third of telomere length, using combined
information from 10 studies was 1.42 (95% confidence interval
1.11 to 1.81), with no significant heterogeneity between studies
(I2=41%, 95% confidence interval 0% to 72%; Phet=0.08) (fig
3⇓). The association with cerebrovascular disease remained
significant in meta-analyses restricted to four studies that
adjusted for conventional vascular risk factors (relative risk
1.54, 1.17 to 2.02) and in four studies with ≥200 cases (1.42,
1.05 to 1.92) (see fig 5 in appendix). Results of meta-analyses
were not significant in the four highest quality studies (1.21,
0.83 to 1.76) nor in six prospective studies (1.14, 0.85 to 1.54)
(fig 3⇓ and fig 5 in appendix). There was little evidence of
publication bias among studies of cerebrovascular disease
(PEgger=0.64).
Discussion
Principal findings
This meta-analysis indicates that telomere length is inversely
associated with risk of coronary heart disease independently of
conventional vascular risk factors. The association was broadly
consistent across all study level characteristics tested, including
clinically relevant subgroups, such as different mean ages and
sex distribution, and across prospective and retrospective studies.
In addition, the association with coronary heart disease remained
significant in analyses that made allowance for publication bias
and in analyses restricted to studies with comprehensive
adjustment for potential confounders, in larger studies (that is,
those with ≥200 cases), and in the studies with a higher quality
score.
The association between shorter telomeres and cerebrovascular
disease was comparable with the association with coronary heart
disease. It was not, however, significant in meta-analyses
restricted to prospective studies or the higher quality studies.
Further well powered prospective studies are required to clarify
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the association between telomere length and cerebrovascular
disease.
Finally, there was an inverse correlation in our meta-analysis
between telomere length and age that was weaker than the
correlation reported in a previous systematic review42 (r=−0.13
v r=−0.30). This could be because of differences among the
studies included in the two reviews. For example, we observed
that the correlation with age was stronger in studies of higher
quality, more variable age, and larger size.
Association or causation
There was a significant inverse association between telomere
length and coronary heart disease in studies that used
comprehensive statistical adjustment for potential confounders.
As our meta-analysis was based on results from observational
studies, however, the association could still be subject to residual
confounding or reverse causation bias and therefore does not
allow inference of a cause-effect association. In a recent
meta-analysis of 14 genome-wide association studies (GWAS),43
involving up to 22 233 people with coronary heart disease and
64 762 controls of European descent, seven single nucleotide
polymorphisms (SNPs) were identified that each explained <1%
of the variation in mean leucocyte telomere length. When all
seven polymorphisms were combined into a single genetic risk
score, the alleles associated with shorter telomere length were
also associated with increased risk of coronary heart disease.
The reported genetic effect would be equivalent to a relative
risk of 1.67 (95% confidence interval 1.12 to 2.56) in the shortest
versus longest third of the telomere length distribution. As
genotypes are randomly determined at conception and are
therefore not generally susceptible to reverse causation bias and
confounding,44 estimates from genetic analyses can be viewed
as causal. The genetic effect estimate is compatible with the
observational estimate of 1.54 (1.30 to 1.83) in our
meta-analysis.
As to the mechanisms of a causal association, telomere
shortening might contribute to atherosclerosis through various
biological ageing pathways, such as cellular senescence. For
example, the accumulation of senescent cells, a prominent
feature of atherosclerotic plaques, reduces the regenerative
potential of affected tissues and promotes apoptosis, which can
further exacerbate inflammatory reactions, and endothelial
dysfunction.45 46 It has also been hypothesised that, by reducing
the proliferative potential of vascular smooth muscle cells,
cellular senescence promotes the thinning of fibrous caps and
the instability of atherosclerotic plaques.47 As to potential
therapeutic interventions to modify telomere length, ectopic
expression of telomerase or telomerase reverse transcriptase
can reverse some of the effects of cellular senescence, such as
the loss of the proliferative potential of vascular smooth muscle
cells and endothelial dysfunction.45 47
Strengths and limitations
As far as we are aware, this is the first systematic review and
meta-analysis of the association between telomere length and
risk of coronary heart disease and cerebrovascular disease in
general populations. The existence of widely varying methods
for reporting associations in the literature has made comparing
results across studies challenging. By harmonising the reported
associations across studies to a common scale, however, we
were able to quantify the magnitude of the association between
telomere length and cardiovascular disease in general
populations, to explore sources of heterogeneity between studies,
and to estimate the potential impact of publication bias.
Our review also has some limitations. Firstly, the results of this
meta-analysis were based on telomere length measured in blood
leucocytes, and telomere shortening in more relevant tissues,
such as the vasculature, might show stronger associations with
coronary heart disease. Nevertheless, telomere length within
individuals is generally strongly correlated across tissues,
suggesting that leucocyte measures accurately reflect the same
construct in other tissues.4 Secondly, we were unable to test the
shape of the association between telomere length and coronary
heart disease or cerebrovascular disease. If the association were
non-linear, telomere length at different thresholds might show
stronger associations. Thirdly, our results reflect the
measurement of telomere length at a single time point, and
longitudinal changes in telomere length might show stronger
associations with risk of cardiovascular disease.22 48 Fourthly,
the results of the included studies reflect average telomere length
measured across all chromosomes. Measurement of telomere
length of individual chromosomes might be more important, as
telomeric dysfunction of one chromosome is sufficient to induce
cell apoptosis.49 Such detailed measurements, however, are
currently not feasible in large scale epidemiological studies.
Fifthly, our meta-analysis was limited to aggregate data obtained
from the published literature and through correspondence.
Access to individual participant data would allow detailed
characterisation of the shape of any dose-response relations,
consistent statistical adjustment for potential confounders across
studies, direct comparison of telomere length with traditional
cardiovascular risk factors, assessment of the associations of
telomere length in different population subgroups, and
exploration of the usefulness of telomere length in prediction
of risk of cardiovascular disease by calculation of risk prediction
metrics, such as risk discrimination and risk reclassification.
Should measurement of telomere length be
offered as a marker of age related chronic
diseases?
In 2010, two companies in the United States and Spain were
founded that offer telomere length measurement services,
claiming that shorter telomere length is a reliable marker of
many age related chronic diseases. By 2013, one company
(www.lifelength.com) offeredmeasurement to the general public
(through a requesting physician or laboratory) and the other
(www.telomeredx.com) stated they intended to do so soon.
Whether telomere testing can provide reliable information about
risk of chronic disease to individuals from the general
population, however, has not been firmly established.6-8 50 For
example, in a meta-analysis involving 26 studies and 11 255
patients with cancer, telomere length was not associated with
cancer risk in the subset of studies with a prospective design.
In our meta-analysis, shorter telomeres were associated with
coronary heart disease under a wide range of circumstances,
but the association with cerebrovascular disease did not persist
in prospective studies or the highest quality studies. Although
our meta-analysis suggests that telomere length is an
independent risk factor for coronary heart disease, judgment on
whether it is a clinically useful predictor of risk that can help
guide treatment decisions will require formal evaluation of its
predictive value in large prospective studies with long follow-up.
Conclusions
Available observational data show an inverse association
between telomere length and risk of coronary heart disease,
independent of conventional vascular risk factors. The
association with cerebrovascular disease is less certain.
Additional meta-analyses based on individual participant data
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are required to characterise the shape of any dose-response
associations, to further characterise the nature of the association
in different population subgroups, and to explore the usefulness
of telomere length in prediction of risk of cardiovascular disease.
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Table
Table 1| Selected characteristics of 24 vascular disease studies included in review of leucocyte telomere length and risk of cardiovascular
disease
No of
CEVD
cases
No of
CHD
cases
Cohort
size or No
of controls
CEVD
definition
CHD
definition
Assay
methodMen (%)
Mean age
(SD)
NOS
quality
score
Population source
(overall or of cases
/ controls)Location
Prospective studies
4643800Ischaemic
stroke
MixedqPCR4962.7 (11.1)9Population based
cohort
ItalyBRUNECK37
1530124UnclassifiedFatalqPCR5071.5 (7.9)4Family linkage studyUSCawthon19
—6999765—MixedqPCR4559.0 (16.7)8Population based
cohort
DenmarkCCHS36
—23010 073—MixedqPCR4856.5 (13.5)8Population based
cohort
DenmarkCGPS36
—36419—MixedSB4174.4 (5.2)8Insurance registerUSCHS23
43—1004Ischaemic
stroke
—SB3573.9 (4.7)8Insurance registerUSCHS24
691892721UnclassifiedFatalqPCR4973.6 (2.9)7Insurance register
and area code
residence
USHABC29
—29235—FatalqPCR4973.7 (2.9)3High functioning
subset of EPESE
USMAHAS22
—226444*—MixedqPCR6961.0 (5.1)7Population based
cohort
SwedenMDC30
392—392*Ischaemic
stroke
—qPCR061.4 (5.9)8Occupational listUSANHS33
—1641917—MixedqPCR4946.6 (18.4)8Population based
cohort
CanadaNSHS9538
259—259*Ischaemic
stroke
—qPCR10061.7 (7.9)8Occupational listUSPHS40
—337337*—MixedqPCR10060.1 (8.7)8Occupational listUSPHS39
—289517*—MixedqPCR10056.7 (5.2)8GP registerScotlandWOSCOPS14
Retrospective studies
—203180*—Non-fatalSB8647.2 (5.9)5Hospital register/GP
register
UKBrouilette18
—21402211*—Non-fatalqPCR5458.6 (9.4)7Hospital
patients/community
sample
ChinaCui20
—42762—Non-fatalqPCR4760.5 (10.2)7Population based
cohort
CyprusCYPRUS31
1081—1081*Ischaemic
stroke
—qPCR6661.4 (9.8)7Hospital
patients/community
sample
ChinaDing21
—520559*—Non-fatalqPCR10051.5 (5.5)6Hospital
patients/community
sample
Multiple†HIFMECH27
150—150*Ischaemic
stroke
—qPCR7452.2 (8.1)6Hospital
patients/community
sample
ChinaJiang25
-51679—Non-fatalqPCR2789.7 (3.0)4Population based
cohort
NetherlandsL85+26
767—1801*Ischaemic
stroke
—qPCR5759.7 (8.2)6Hospital
patients/hospital
patients
ChinaMCSS41
—76238*—Non-fatalqPCR7856.9 (11.0)5Hospital
patients/community
sample
IndiaMukherjee28
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(continued)
No of
CEVD
cases
No of
CHD
cases
Cohort
size or No
of controls
CEVD
definition
CHD
definition
Assay
methodMen (%)
Mean age
(SD)
NOS
quality
score
Population source
(overall or of cases
/ controls)Location
—199190*—Non-fatalqPCR9139.8 (5.0)6Hospital
patients/unspecified
ItalyRusso32
1238190UnclassifiedNon-fatalqPCR8279.0 (0)5Population based
cohort
UKSMS‡35
—2513*—Non-fatalFISH10065.1 (2.1)3Hospital
patients/volunteers
GermanySpyridopoulos34
CEVD=cerebrovascular disease; CHD=coronary heart disease; FISH= flow cytometry-fluorescent in situ hybridisation; NOS= Newcastle-Ottawa scale; qPCR=
quantitative polymerase chain reaction; SB= Southern blotting; CCHS=Copenhagen City Heart Study; CGPS=Copenhagen General Population Study;
CHS=Cardiovascular Health Study; EPESE=Established Populations for the Epidemiologic Study of the Elderly; HABC=Health Aging and Body Composition Study;
HIFMECH=Hypercoagulability and Impaired Fibrinolytic function MECHanisms predisposing to myocardial infarction; L85+=Leiden 85-plus study; MAHAS=MacArthur
Health Aging Study; MCSS=Multicenter Chinese Stroke Study; MDC=Malmö Diet and Cancer Study; NHS=Nurses’ Health Study; NSHS95=1995 Nova Scotia
Health Survey; PHS=Physicians’ Health Study; SMS=Scottish Mental Survey; WOSCOPS=West of Scotland Coronary Prevention Study.
*Number of controls in case-control study.
†Sweden, England, France, Italy.
‡Findings for CEVD previously unpublished.
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Figures
Fig 1 Shorter telomere length and risk of coronary heart disease across 20 studies stratified by study design (see table for
study acronyms). Study specific estimates were pooled with random effects meta-analysis. Sizes of data markers are
proportional to inverse of variance within study. Degree of adjustment: − no adjustment, + adjusted for age and/or sex, ++
adjusted for age, sex, and non-lipid risk factors, +++ adjusted for age, sex, smoking, BMI, diabetes, blood pressure, and
lipid markers; ++++ preceding plus adjusted for C reactive protein and physical activity. *Calculated from mean difference
in telomere length between cases and controls; †obtained through correspondence. Summary associations for prospective
and retrospective studies were not significantly different (P=0.32)
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Fig 2 Shorter telomere length and risk of coronary heart disease grouped by recorded study level characteristics. Sizes of
data markers are proportional to inverse of variance of relative risk. NR=not reported; NOS=Newcastle-Ottawa scale. *P
values for heterogeneity from meta-regression; studies in which characteristic was not reported were not included in
calculation of P value; for continuous characteristics, P value reflects linear test of association. †Population source of cohort
or controls in case-control studies. Degree of adjustment: −/+ no adjustment or adjusted for age and/or sex, ++adjusted for
age, sex, and non-lipid risk factors, +++adjusted for age, sex, BMI, diabetes, smoking, blood pressure, and lipid markers,
++++adjusted for preceding plus C reactive protein and physical activity
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Fig 3 Shorter telomere length and cerebrovascular disease risk across 10 studies stratified by study design (see table for
study acronyms). Study specific estimates were pooled with random-effects meta-analysis. Sizes of data markers are
proportional to inverse of variance within study. Degree of adjustment: +adjusted for age and/or sex, ++adjusted for age,
sex, and non-lipid risk factors, +++adjusted for age, sex, smoking, BMI, diabetes, blood pressure, and lipid markers,
++++adjusted for preceding plus C reactive protein and physical activity. *Calculated from mean difference in telomere
length between cases and controls; †obtained through correspondence; ‡previously unpublished. Summary associations
for prospective and retrospective studies were not significantly different (P=0.15)
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